Deals in Depth: June/July 2010

Article preview from In-Vivo - September, 2010

Front-runners for June alliances were J&J's $586 million respiratory deal with Orexo and Bayer Schering's cancer partnership with OncoMed valued at about $540 million. Leading the pack for biopharma M&A was Grifol's $3.4 billion bid (plus $600 million in debt) for privately owned Talecris. In financings, both biopharma and device companies were busy raising private money, bringing in over $1.3 billion in June and July (compared with only $157 million in public sales).

Deals in Depth: June/July 2010

Article preview from In-Vivo - September, 2010

June/July 2010 dealmaking highlights:

Biopharma alliance dollars for both June and July increased dramatically over May's activity. Front-runners for June were J&J's $586 million respiratory deal with Orexo and Bayer Schering's cancer partnership with OncoMed valued at about $540 million.

M&A deals were far stronger in June over July, with more than $17 billion committed in that month among the top four in biopharma and one on the device side. Leading the pack was Grifol's $3.4 billion bid (plus $600 million in debt) for privately owned Talecris.

Over the two months, public financing activity was much slower than during the spring. Both biopharma and device were busy raising private money, however, bringing in over $1.3 billion in June and July (compared with only $157 million in public sales).

Continued...

Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512